Rozaleen Dash

A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.

The authors review some of the monoclonal antibody candidates that reached Phase III clinical trials but were discontinued at later stages.

The authors review some of the monoclonal antibody candidates that reached Phase III clinical trials but were discontinued at later stages.

A major advantage of SPR-based analysis is its ability to estimate the association and dissociation rate constants, an advancement over the traditional steady-state analysis of biomolecules.